-
公开(公告)号：WO2018074770A1
公开(公告)日：2018-04-26
申请号：PCT/KR2017/011172
申请日：2017-10-11
Applicant: 서울대학교산학협력단
IPC: A61K48/00 , G01N33/574 , G01N33/50 , C12Q1/68
Abstract: 본원은 RNF20의 신장암 또는 간암의 치료제 및 진단용 마커로서의 용도를 개시한다. 또한 본원은 RNF20-SREBP1c-PTTG1 및 RNF20-SREBP1c-지방생합성 경로를 기반으로 하는 새로운 분자기전을 이용한 RNF20의 이상과 관련된 암 치료제 스크리닝 방법을 개시한다.
Abstract translation:
本申请公开了使用作为RNF20的肾脏或肝脏癌症治疗剂和诊断用标记物。 此外，本申请公开了一种方法，用于筛选与RNF20的至少使用基于RNF20-SREBP1c-PTTG1和RNF20-SREBP1c-的一个新的分子机制脂肪生物合成途径相关的癌症。
-
公开(公告)号：KR101983435B1
公开(公告)日：2019-09-03
申请号：KR1020160136569
申请日：2016-10-20
Applicant: 서울대학교산학협력단
IPC: A61K48/00 , G01N33/574 , G01N33/50 , C12Q1/68
-
公开(公告)号：KR1020110063621A
公开(公告)日：2011-06-13
申请号：KR1020110035147
申请日：2011-04-15
Applicant: 서울대학교산학협력단
Abstract: PURPOSE: A novel lipase induced by fasting and a gene encoding the same are provided to develop a therapeutic agent for obesity and to be used in foods, detergents, fine chemicals, and cosmetics. CONSTITUTION: A novel lipase induced by fasting contains an amino acid sequence of sequence number 2. A lipase gene encoding the lipase has a base sequence of sequence number 4. A recombinant vector contains the lipase gene. The lipase gene is fil-1 and fil-2 genes. The novel lipase is prepared by introducing fil-1 and fil-2 genes to wild type C. elegans and transforming an insect.
Abstract translation: 目的：提供通过禁食诱导的新型脂肪酶和编码其的基因，以开发用于肥胖症的治疗剂并用于食品，洗涤剂，精细化学品和化妆品中。 构成：通过禁食诱导的新型脂肪酶含有序列号2的氨基酸序列。编码脂肪酶的脂肪酶基因具有序列号4的碱基序列。重组载体含有脂肪酶基因。 脂肪酶基因是fil-1和fil-2基因。 通过将fil-1和fil-2基因导入野生型秀丽隐杆线虫并转化昆虫来制备新型脂肪酶。
-
公开(公告)号：KR101572322B1
公开(公告)日：2015-11-26
申请号：KR1020130136827
申请日：2013-11-12
Applicant: 서울대학교산학협력단
Abstract: 본발명은 DNMT1을이용한비만또는대사성질환치료제스크리닝방법에관한것으로서, 세포를배양하는단계; 상기세포에후보물질을처리하는단계; 상기세포에서아디포넥틴프로모터의메틸화를측정하는단계; 및상기아디포넥틴프로모터의메틸화가대조군에비해감소된것을확인하는단계를포함하는것을특징으로하는비만또는대사성질환치료제스크리닝방법을제공한다. 또한, DNMT1 활성억제제를포함하는비만또는대사성질환치료제를제공한다.
-
公开(公告)号：KR1020150054415A
公开(公告)日：2015-05-20
申请号：KR1020130136827
申请日：2013-11-12
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/5044 , C12Y201/01037 , G01N2333/46 , G01N2333/91017
Abstract: 본발명은 DNMT1을이용한비만또는대사성질환치료제스크리닝방법에관한것으로서, 세포를배양하는단계; 상기세포에후보물질을처리하는단계; 상기세포에서아디포넥틴프로모터의메틸화를측정하는단계; 및상기아디포넥틴프로모터의메틸화가대조군에비해감소된것을확인하는단계를포함하는것을특징으로하는비만또는대사성질환치료제스크리닝방법을제공한다. 또한, DNMT1 활성억제제를포함하는비만또는대사성질환치료제를제공한다.
Abstract translation: 本发明涉及用DNMT1筛选肥胖或代谢紊乱的治疗剂的方法。 该方法包括以下步骤：培养细胞; 在细胞上加工候选物质; 测量细胞中脂联素启动子的甲基化; 检查脂联素启动子的甲基化是否低于对照组。
-
Patent Agency Ranking
公开(公告)号：KR1020100086390A
公开(公告)日：2010-07-30
申请号：KR1020090005749
申请日：2009-01-22
Applicant: 서울대학교산학협력단
CPC classification number: C12N9/20 , A23L29/06 , C11D3/38627
Abstract: PURPOSE: A novel lipase which is induced by fasting is provided to develop a therapeutic agent for obesity relating to lipid granule and to use in industries such as food, detergent, and cosmetics. CONSTITUTION: A novel lipase which is induced by fasting has an amino acid sequence of sequence number 1 or 2. A gene encoding the lipase of sequence number 1 has base sequence of sequence number 3. A gene encoding the lipase of sequence number 2 has base sequence number 4. A recombinant vector contains the lipase gene having sequence number 3 or 4. The recombinant vector is an expression vector.
Abstract translation: 目的：提供一种通过禁食诱导的新型脂肪酶，以开发与脂质颗粒相关的肥胖症治疗剂，并用于食品，洗涤剂和化妆品等行业。 构成：通过空腹诱导的新型脂肪酶具有序列号1或2的氨基酸序列。编码序列号1的脂肪酶的基因具有序列号3的碱基序列。编码序列号2的脂肪酶的基因具有碱基 序列号4.重组载体含有序列号3或4的脂肪酶基因。重组载体是表达载体。
-
-
公开(公告)号：KR101215759B1
公开(公告)日：2012-12-26
申请号：KR1020100107460
申请日：2010-11-01
Applicant: 서울대학교산학협력단
Inventor： 김재범
IPC: A61K38/17 , A61K38/16 , A61K39/235 , A61P3/00
Abstract: 본발명은 ORM(Orosomucoid) 유전자또는단백질을포함하는대사질환의예방또는치료용조성물에관한것이다. 본발명의조성물은생체내 풍부하게존재하는천연물질인 ORM을포함하며다양한타겟에대해선택적인조절활성을갖기때문에대사질환에따른제반증상을예방또는치료하는데효과적으로사용할수 있으며제조가간편하고부작용의발생가능성이적은특징을갖는다.
-
公开(公告)号：KR1020120045725A
公开(公告)日：2012-05-09
申请号：KR1020100107460
申请日：2010-11-01
Applicant: 서울대학교산학협력단
Inventor： 김재범
IPC: A61K38/17 , A61K38/16 , A61K39/235 , A61P3/00
CPC classification number: A61K38/1709 , Y10S514/909
Abstract: PURPOSE: A composition containing ORM gene or protein is provided to prevent or treat metabolic diseases and to selectively control activity to various targets. CONSTITUTION: A pharmaceutical composition for preventing or treating metabolic diseases contains pharmaceutically acceptable amount of ORM(orosomucoid) gene or protein as an active ingredient and pharmaceutically acceptable carrier. The ORM includes ORM isomers of ORM1, ORM2 or ORM3. The metabolic diseases are hyperlipidemia, fatty liver, diabetes, or obesity.
Abstract translation: 目的：提供含有ORM基因或蛋白质的组合物，以预防或治疗代谢疾病，并选择性地控制各种靶标的活性。 构成：用于预防或治疗代谢疾病的药物组合物含有药学上可接受量的作为活性成分和药学上可接受的载体的ORM（orosomucoid）基因或蛋白质。 ORM包括ORM1，ORM2或ORM3的ORM异构体。 代谢疾病是高脂血症，脂肪肝，糖尿病或肥胖。
-
公开(公告)号：KR1020120058370A
公开(公告)日：2012-06-07
申请号：KR1020107014488
申请日：2007-11-29
Applicant: 서울대학교산학협력단
IPC: A61K31/4375 , A61P19/10 , A61P19/00
CPC classification number: A61K31/4375
Abstract: PURPOSE: A composition containing berberine is provided to promote Runx2 acitvation and to treat bone-related diseases including osteoporosis. CONSTITUTION: A composition for promoting osteoblast differentiation contains therapetucially effective amount of berberine and pharmaceutically acceptable carrier or additive. The composition selectively contains at least one adjuvant. A pharmaceutical composition for treating bone-related diseases contains therapeutically effectively amount of berberine. The bone-related diseases include osteoporosis, osteopenia, fracture, or bone density reduction.
Abstract translation: 目的：提供含有小檗碱的组合物，以促进Runx2的治疗，并治疗包括骨质疏松症在内的骨相关疾病。 构成：用于促进成骨细胞分化的组合物含有治疗有效量的小檗碱和药学上可接受的载体或添加剂。 组合物选择性地含有至少一种佐剂。 用于治疗骨相关疾病的药物组合物含有治疗有效量的小檗碱。 骨相关疾病包括骨质疏松症，骨质减少，骨折或骨密度降低。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.022 seconds)
